Funding profile · Heart failure devices

Selera Medical

One reported round of $500,000, no Form D on file, no federal grants, and a single registered trial that was withdrawn before it enrolled anyone. The capital picture here is short because the capital was short.

$500KTotal reported funding, one seed round dated April 2024
$0Capital visible in SEC Form D filings
$0Federal grant money on record from NIH or NSF
0Patients enrolled in the one registered trial

Data as of September 24, 2026. Company-reported and data provider figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Winter 2024 Y Combinator batch Standard deal, $500,000 Y Combinator YC terms page
Apr 2024 Seed $500,000 1 institutional investor, not named Data provider
To Sep 2026 Regulation D offerings None on file None SEC EDGAR
To Sep 2026 Federal grants None None NIH, NSF
To Sep 2026 Any later round None reported None Not found

What the filings show

Selera Medical, Inc. · no Form D located · searched Sep 24, 2026

Full text search
EDGAR full text search returns 0 documents for “Selera Medical” and 0 for “Arechavala”
Company search
EDGAR company search for names beginning with selera, form type D, returns no matching companies
Automated pull
0 parsed Form D filings and 0 EDGAR Form D filings mentioning the company
CIK
None found
Reading
Either the money moved outside Regulation D, or a required notice was not filed

Reading the filings

  1. The whole capital base is one accelerator check.Tracxn records $500,000 in one seed round dated April 2024 with one institutional investor. That divides to $500,000 per investor, which is not a syndicate. It is also the exact size of Y Combinator’s published standard deal: $125,000 on a post money SAFE for 7 percent, plus $375,000 on an uncapped most favored nation SAFE. The company was in the Winter 2024 batch.
  2. There is nothing in EDGAR to read.No Form D exists under any Selera name. A SAFE sold to accredited investors is usually notified on Form D within 15 days of first sale, so the gap is worth noting, but issuers that rely on Section 4(a)(2) instead of Regulation D file nothing, and accelerator SAFEs are often papered that way. The absence proves no capital either way; it only means the public filing trail is empty.
  3. Non dilutive capital is zero.No NIH award, no NSF award, no SBIR or STTR. For a preclinical cardiovascular device that is unusual, and it removes the cushion that carries device startups through the years before first in human data.
  4. The money never reached a patient.The one registered study, NCT06554912, was posted in August 2024 and updated to WITHDRAWN in December 2024 with actual enrollment of 0. The registry gives the reason as “stop financial collaboration”. A sponsor and a site were in place; the funding for the collaboration was not.
  5. The burn ran out before the evidence started.The protocol called for contrast CT, right heart catheterization, thoracic duct access, stenting and six months of follow up per patient at a French university hospital. Against that, $500,000 is the entire reported capital base, spread across a two person team from 2023 onward.
  6. The register now reads as closed.The Y Combinator directory record carries the status value Inactive and flags both founders as no longer active, and seleramedical.com has shown the same “Coming Soon” placeholder from March 2024 to September 2026.

Commercial signals

Signal Detail Source type
Regulatory No FDA clearance, approval, breakthrough designation or investigational device exemption on record. Nothing is authorized. Public record
Product No marketed product. Company website is a placeholder page. Public record
Clinical evidence One registered trial, withdrawn, 0 enrolled. No publications. Public record
Headcount Team size 2 in the YC record; Tracxn shows 3 as of Jun 2026. Data provider
Category comparison WhiteSwell, working the same lymphatic decongestion thesis, holds FDA breakthrough device designation and reported 40 patient DELTA-HF results in May 2026, with a randomized trial planned. Independent

What to watch

  • Any Form D appearing under a Selera entity, which would be the first sign of new capital.
  • A published patent application naming Selera Medical, which would be the one transferable asset.
  • Whether the Grenoble protocol is refiled with a different collaborator.
  • Where the two founders land, and whether the approach follows them.

The Selera Medical story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Corveus Medical: Also in Medical Devices. A Houston company building a catheter that deactivates one sympathetic nerve to relieve congestion in heart failure
  • VenoStent: Also in Medical Devices. A bioabsorbable polymer sleeve that a surgeon slips over a newly built dialysis fistula and leaves behind to dissolve
  • InnoVein: Also in Medical Devices. A prosthetic valve for the deep veins of the leg, aimed at a disease with no cure and at a device category that has never reached market
  • Vena Vitals: Also in Medical Devices. A soft sticker, built on wrinkled metal from a UC Irvine lab, that reads blood pressure beat by beat

Sources

  1. Public recordSEC EDGAR full text search and company search for Selera Medical, no Form DSEC · Sep 24, 2026
  2. Public recordClinicalTrials.gov NCT06554912, FLOWS-HF, withdrawn, actual enrollment 0Posted Aug 15, 2024, updated Dec 20, 2024
  3. Public recordY Combinator company directory record for Selera MedicalY Combinator · Sep 24, 2026
  4. Public recordFDA device databases, NIH RePORTER and NSF award pullsRecords file · Sep 24, 2026
  5. Public recordseleramedical.com home page, archived and liveInternet Archive and live · Mar 2024 to Sep 2026
  6. Data providerSelera Medical company profile, funding and employee countTracxn · Sep 24, 2026
  7. InterviewNew CAP Selera Takes an Innovative Approach to Managing Chronic Heart FailureFogarty Innovation · Dec 19, 2023
  8. CompanyThe Y Combinator Standard DealY Combinator · accessed Sep 24, 2026
  9. CompetitorWhiteSwell Announces Primary Clinical Trial Results, DELTA-HFWhiteSwell · May 10, 2026

Compiled from SEC, FDA, NIH, NSF and ClinicalTrials.gov public records and published reports as of September 24, 2026. Form D notices report offerings under Regulation D; an absent notice does not by itself establish that no securities were sold. Healthcare Venture Capital Fund holds no position in Selera Medical. This page is not an offer to sell or a recommendation to buy any security.